-
Aquestive Therapeutics Inc. (AQST) Prices 7M Share Common Offering at $5/Sh
-
Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock
-
Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock
-
Aquestive Therapeutics (AQST) Announces Proposed $35M Public Offering of Common Stock
-
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
-
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
-
Aquestive Therapeutics (AQST) PT Lowered to $19 at BMO Capital
-
Aquestive Therapeutics (AQST) PT Lowered to $21 at BMO Capital
-
Aquestive (AQST) Sublingual Apomorphine Delay 'Not Too Significant' - BMO
-
Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
-
Aquestive Therapeutics (AQST) PT Lowered to $24 at BMO Capital
-
BMO Capital Starts Aquestive Therapeutics (AQST) at Outperform
-
Aquestive Therapeutics Announces Closing of Exercise of Underwriters' Over-Allotment Option in Initial Public Offering
-
Aquestive Therapeutics Announces Closing of Initial Public Offering
-
Aquestive Therapeutics, Inc. (AQST) Prices 4.5M Share IPO at $15/Sh
-
Aquestive Therapeutics Announces Pricing of Initial Public Offering